Edition:
United States

People: Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

18.46USD
13 Aug 2018
Change (% chg)

$-0.02 (-0.11%)
Prev Close
$18.48
Open
$18.43
Day's High
$18.57
Day's Low
$18.02
Volume
43,606
Avg. Vol
168,130
52-wk High
$31.69
52-wk Low
$12.51

Grossi, Federico 

Mr. Federico Grossi M.D. Ph.D., is Executive Vice President - Clinical Development of the Company. Dr. Grossi was Potentia Pharmaceuticals’ Clinical Research Director when he joined Apellis as the new company’s Clinical Research Director in 2010. Dr. Grossi received his medical degree from the University of Cordoba in Argentina and his Doctorate’s Degree in Physiology from the University of Louisville. Following his post graduate training in surgery, Dr. Grossi joined the Plastic Surgery Research Laboratory at the University of Louisville where he developed his expertise in microsurgery and composite tissue transplantation. He was a crucial member of the Louisville Face Transplant Team, which has published several manuscripts on the ethical and psychological aspect of face transplantation that are now considered hallmark publications in this field. He has also published numerous articles in the fields of ischemic preconditioning and composite tissue allotransplantation.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --